Legato Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Legato Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.63M	Buy	15,538 +5,911	+61%	+$1.02M	0.24%	118
2025 Q4	$1.76M	Buy	9,627 +4,576	+91%	+$639K	0.15%	211
2025 Q3	$613K	Buy	5,051 +750	+17%	+$84.5K	0.07%	414
2025 Q2	$449K	Sell	4,301 -5,680	-57%	-$601K	0.05%	452
2025 Q1	$1.16M	Buy	+9,981	New	+$1.14M	0.16%	211
2024 Q2	–	Sell	-4,733	Closed	-$378K	–	564
2024 Q1	$378K	Sell	4,733 -3,889	-45%	-$326K	0.05%	481
2023 Q4	$686K	Hold	8,622	–	–	0.09%	350
2023 Q3	$603K	Sell	8,622 -3,330	-28%	-$249K	0.09%	355
2023 Q2	$859K	Buy	11,952 +4,925	+70%	+$363K	0.12%	291
2023 Q1	$433K	Hold	7,027	–	–	0.08%	379
2022 Q4	$542K	Buy	+7,027	New	+$420K	0.1%	329

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legato Capital Management's AXSM Position: Q1 2026 in Review

Legato Capital Management increased its Axsome Therapeutics (AXSM) stake by 61% in Q1 2026, buying an estimated $1.02M and bringing the position to 15,538 shares worth $2.63M. The position accounts for 0.24% of the portfolio, ranked #118.

Legato Capital Management first reported a position in AXSM in Q4 2022 and has held it in 11 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Legato Capital Management held 15,538 shares of Axsome Therapeutics worth $2.63M as of Q1 2026.
Legato Capital Management bought 5,911 Axsome Therapeutics shares in Q1 2026, an estimated $1.02M.
Axsome Therapeutics made up 0.24% of Legato Capital Management's portfolio in Q1 2026, its #118 holding.
Legato Capital Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 11 quarters since.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.